<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03595917</url>
  </required_header>
  <id_info>
    <org_study_id>18-170</org_study_id>
    <nct_id>NCT03595917</nct_id>
  </id_info>
  <brief_title>ABL001 + Dasatinib + Prednisone in BCR-ABL+ B-ALL or CML</brief_title>
  <official_title>A Phase 1 Study of ABL001 in Combination With Dasatinib and Prednisone in Patients With BCR-ABL Positive (BCR-ABL+) B-cell Acute Lymphoblastic Leukemia (B-ALL) and Chronic Myeloid Leukemia (CML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marlise R. Luskin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is evaluating a drug called ABL001 taken in combination with dasatinib
      (Sprycel®) and prednisone (a steroid) as a possible treatment for B-cell Acute Lymphoblastic
      Leukemia that is BCR-ABL positive (BCR-ABL+ B-ALL) or Chronic Myeloid Leukemia (CML) in
      lymphoid blast crisis. BCR-ABL+ B-ALL is also called Philadelphia chromosome positive Acute
      Lymphoblastic Leukemia (Ph+ ALL).

      It is expected that 25-34 people will take part in this research study.

        -  ABL001

        -  Dasatinib (Sprycel®)

        -  Prednisone
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research study is a Phase I clinical trial, which tests the safety of an investigational
      drug and also tries to define the appropriate dose of the investigational drug to use for
      further studies. &quot;Investigational&quot; means that the drug is being studied.

      There is currently no clinical data on the effects of ABL001 in combination with dasatinib
      and prednisone among adults with Ph+ B-ALL or CML in lymphoid blast crisis. However, there is
      data on the use of ABL001 in combination with dasatinib (without steroids) in patients with
      relapsed Ph+ B-ALL and Ph+ chronic myeloid leukemia (CML).

      Dasatinib (Sprycel®) is currently approved for the treatment in newly diagnosed adults with
      Ph+ CML in chronic phase (CP), adults with chronic, accelerated, or myeloid or lymphoid blast
      phase Ph+ CML with resistance or intolerance to prior therapy including imatinib, adults with
      Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or
      intolerance to prior therapy.

      ABL001 is a newly discovered compound. This drug has been used in laboratory experiments and
      information from those experiments suggest that this drug may have beneficial effects in
      people who have CML or Ph+ ALL, both of which are a certain type of cancer of the blood
      cells. The reason for this study is to learn whether ABL001 is safe and can have possible
      benefits for people with Ph+ ALL who are also being treated with dasatinib and prednisone,
      two drugs which are commonly used to treat Ph+ ALL. All participants in this study will
      receive all three drugs.

      Prednisone and dasatinib are both FDA approved and standard of care for participants with
      your disease. They are not considered investigational on this study. However, ABL001 is being
      tested in combination with these drugs.

      Biomarker testing will also be included in this study. Biomarkers are important biological
      &quot;indicators&quot; of whether a drug is working which can be measured from bone marrow and blood
      samples.

      In addition, blood and bone marrow samples may be tested to try to learn more about the
      cancer, and to understand how the drug may be working in cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 24, 2018</start_date>
  <completion_date type="Anticipated">November 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of ABL001</measure>
    <time_frame>42 Days</time_frame>
    <description>To define the maximum tolerated dose (MTD) of ABL001 for participants with BCR-ABL positive (BCR-ABL+) B-cell acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML) in lymphoid blast crisis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage for Participants Achieving Hematologic Remission</measure>
    <time_frame>28 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage for Participants Achieving Hematologic Remission</measure>
    <time_frame>56 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage for Participants Achieving Hematologic Remission</measure>
    <time_frame>85 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving cytogenetic response</measure>
    <time_frame>28 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving cytogenetic response</measure>
    <time_frame>56 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving cytogenetic response</measure>
    <time_frame>85 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving a minimal residual disease (MRD)-negative CR by flow cytometry</measure>
    <time_frame>85 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving a minimal residual disease (MRD)-negative CR by flow cytometry</measure>
    <time_frame>28 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving a minimal residual disease (MRD)-negative CR by flow cytometry</measure>
    <time_frame>56 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving molecular response</measure>
    <time_frame>28 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving molecular response</measure>
    <time_frame>56 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving molecular response</measure>
    <time_frame>85 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>B-cell Acute Lymphoblastic Leukemia</condition>
  <condition>Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis</condition>
  <condition>Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL</condition>
  <arm_group>
    <arm_group_label>ABL001, Dasatinib, Prednisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>- Dose escalation will occur conventional Fibonocci 3+3 dose escalation scheme to determine a recommended phase 2 dose (RP2D)
Dasatinib-Fixed doses oral once a day per cycle
ABL001 is administered orally daily per cycle
Prednisone-Fixed doses oral once a day per cycle. --- Prednisone will be tapered and stop during cycle 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABL001</intervention_name>
    <description>•ABL001 is administered daily per 28 day cycle</description>
    <arm_group_label>ABL001, Dasatinib, Prednisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib</intervention_name>
    <description>Fixed doses oral once a day per 28 day cycle</description>
    <arm_group_label>ABL001, Dasatinib, Prednisone</arm_group_label>
    <other_name>Sprycel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Fixed doses oral once a day per 28 day cycle Prednisone will be tapered and stop during cycle 2.</description>
    <arm_group_label>ABL001, Dasatinib, Prednisone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must meet the following criteria on screening examination to be eligible
             to participate in the study:

               -  Participants must have cytopathologically confirmed BCR-ABL+ B-cell ALL or CML in
                  lymphoid blast crisis.20

               -  Patients with p210 (b2a2 or b3a2) and p190 (e1a2 only) transcripts confirmed by a
                  CLIA-certified lab assay will both be eligible.

               -  Patients with asymptomatic central nervous system (CNS) disease are eligible and
                  may be treated concurrently with intrathecal chemotherapy.

               -  Participants must NOT be suitable for or willing to receive standard intensive
                  induction chemotherapy. The following groups are not considered suitable for
                  standard intensive induction chemotherapy:

               -  Participants who have not received standard intensive induction chemotherapy and
                  are aged ≥ 50 years.

               -  Participants who have not received standard intensive induction chemotherapy and
                  are aged 18 to 49 years and unfit due to co-morbidity or other factors to receive
                  intensive chemotherapy. Specific criteria that would suggest that a patient is
                  unsuitable for intensive induction chemotherapy include:

                    -  Severe cardiac comorbidity (congestive heart failure or documented
                       cardiomyopathy with EF ≤50%).

                    -  Severe pulmonary comorbidity (documented pulmonary disease with DLCO ≤ 65%
                       or FEV1 ≤ 65%, or dyspnea at rest, or requiring oxygen).

                    -  ECOG performance status of 2 due to medical conditions unrelated to
                       leukemia.

                    -  Any other comorbidity that the physician judges to be incompatible with
                       intensive cytotoxic chemotherapy.

               -  Participants aged ≥ 18 years with disease that is relapsed or refractory to 1 or
                  more cycles of standard intensive induction chemotherapy.

          -  ECOG performance status 0-3 (Appendix A). ECOG value of 3 is allowed after documented
             discussion with PI, if poor performance status is attributed to underlying disease.

          -  Participants must have normal organ function as defined below:

               -  Creatinine ≤ 1.5x institutional upper limit of normal.

               -  Amylase and lipase values ≤ 3.0x institutional upper limit of normal.

               -  Alkaline phosphatase ≤ 2.5x institutional upper limit of normal unless considered
                  to be not of hepatic origin.

               -  AST(SGOT)/ALT(SGPT) ≤ 3x institutional upper limit of normal.

               -  Total bilirubin ≤ 1.5x institutional upper limit of normal (≤ 3x upper limit of
                  normal in patients with known Gilbert's syndrome).

          -  The effects of ABL001 on the developing human fetus are unknown. For this reason,
             women of child-bearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control; abstinence) prior to study entry and for
             the duration of study participation.

          -  Women of child-bearing potential must agree to use highly effective methods of
             contraception during dosing and for 30 days after study treatment. Should a woman
             become pregnant or suspect she is pregnant while she or her partner is participating
             in this study, she should inform her treating physician immediately.

          -  Allowable methods of birth control:

               -  Total abstinence (when this is in line with the preferred and usual lifestyle of
                  the subject). Periodic abstinence (e.g., calendar, ovulation, symptothermal,
                  post-ovulation methods) and withdrawal are not acceptable methods of
                  contraception.

               -  Female sterilization (have had surgical bilateral oophorectomy with or without
                  hysterectomy), total hysterectomy, or tubal ligation at least six weeks before
                  taking study treatment. In case of oophorectomy alone, only when the reproductive
                  status of the woman has been confirmed by follow up hormone level assessment.

               -  Male sterilization (at least 6 months prior to screening). The vasectomized male
                  partner should be the sole partner for that subject.

               -  Use of oral, injected or implanted hormonal methods of contraception or placement
                  of an intrauterine device (IUD) orintrauterine system (IUS), or other forms of
                  hormonal contraception that have comparable efficacy (failure rate &lt;1%), for
                  example hormone vaginal ring or transdermal hormone contraception.

               -  Sexually active males must use a condom during intercourse while taking the drug
                  and for 30 days after stopping treatment and should not father a child in this
                  period. A condom is required to be used also by vasectomized men in order to
                  prevent delivery of the drug via seminal fluid.

          -  Ability to understand and the willingness to sign a written informed consent document
             and comply with all study procedures.

        Exclusion Criteria

          -  Participants suitable for and willing to receive standard intensive induction
             chemotherapy.

          -  Patients with a known ABL T315I mutation are excluded. ABL kinase mutation analysis is
             not recommended for newly diagnosed patient. ABL kinase mutation analysis is
             recommended for patients with relapsed disease and results should be reviewed prior to
             enrollment.

          -  Prior treatment of ALL or CML with dasatinib or ABL001. Prior receipt of other TKIs
             and chemotherapy for the treatment of ALL or CML is permitted.

          -  Any TKI therapy must be discontinued for 5 half-lives prior to initiation of protocol
             therapy.

          -  Patient may not have received other chemotherapy, including antibody-based therapy,
             within 2 weeks of the initiation of protocol therapy with the exception of steroids or
             hydroxyurea for the control of leukocytosis.

          -  Participants who are receiving any other investigational agents for conditions other
             than ALL must have discontinued those agents 2 weeks prior to the start of study
             treatment.

          -  Impairment of gastrointestinal (GI) function or GI disease that may significantly
             alter the absorption of study drug (e.g., ulcerative disease, uncontrolled nausea,
             vomiting, diarrhea, malabsorption syndrome). Patients who have had a gastrectomy are
             not excluded.

          -  History of another active malignancy within 5 years prior to study entry except for
             previous or concomitant basal cell skin cancer and previous carcinoma in situ treated
             curatively.

          -  Acute or chronic liver disease (including known active hepatitis B and C infections).
             Screening for hepatitis is not required. Patients with treated or past exposure viral
             hepatitis (i.e. evidence of exposure negative viral load) may participate.

          -  History of pulmonary arterial hypertension.

          -  Significant pleural effusions leading to respiratory compromise and need for
             intervention (i.e. thoracentesis).

          -  Alcohol abuse requiring medical treatment.

          -  Participants with a history of acute pancreatitis, chronic pancreatitis, or any
             ongoing pancreatic disease not considered related to ALL.

          -  History of human immunodeficiency virus (HIV). Screening is not required.

          -  History of a serious bleeding disorder unrelated to ALL.

          -  It is suggested that participants receiving treatment with medications that meet one
             of the following criteria discontinue the relevant drug at least one week prior to the
             start of treatment with ABL001 and for the duration of the study. If the medication is
             medically necessary review with PI before enrollment.

               -  Strong inducers of CYP3A4/5.

               -  Moderate and strong inhibitors CYP3A4/5.

               -  CYP3A4/5, CYP2C8 and CYP2C9 substrates with narrow therapeutic index. All other
                  substrates of the enzymes should be used with caution.

               -  H2 antagonists/proton-pump inhibitors.

               -  Grapefruit products are not permitted while on study.

               -  Because the lists of these agents are constantly changing, it is important to
                  regularly consult a frequently-updated list such as
                  http://medicine.iupui.edu/clinpharm/ddis/table.aspx; medical reference texts such
                  as the Physicians' Desk Reference may also provide this information. As part of
                  the enrollment/informed consent procedures, the patient will be counseled on the
                  risk of interactions with other agents, and what to do if new medications need to
                  be prescribed or if the patient is considering a new over-the-counter medicine or
                  herbal product.

          -  Corrected QT interval (QTc) of &gt; 480 milliseconds (ms) on baseline electrocardiogram
             (ECG) (using corrected QT interval per institutional standard).

          -  Major surgery within 2 weeks before the first dose of ABL001.

          -  Uncontrolled intercurrent illness including, but not limited to:

               -  Uncontrolled infection.

               -  Unstable cardiovascular condition including symptomatic congestive heart failure
                  (NYHA class 3 or 4), unstable angina pectoris, ongoing clinically significant
                  cardiac arrhythmia uncontrolled by medication, and myocardial infarction or
                  stroke within the past 3 months.

               -  Psychiatric illness/social situations that would limit compliance with study
                  requirements.

               -  Currently requiring supplemental oxygen, mechanical ventilation, vasopressors,
                  and/or hemodialysis (life-support).

               -  History of significant congenital or acquired bleeding disorder unrelated to
                  cancer.

          -  Unable to comply with an oral regimen.

          -  Are pregnant or nursing at the time of screening. Pregnant women are excluded from
             this study because ABL001 is an agent with the potential for teratogenic or
             abortifacient effects. Because there is an unknown but potential risk for adverse
             events in nursing infants secondary to treatment of the mother with ABL001,
             breastfeeding should be discontinued if the mother is treated with ABL001. These
             potential risks may also apply to other agents used in this study. Urine or serum
             pregnancy test must be performed within 14 days of Day 1 for women of childbearing
             potential
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marlise R. Luskin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marlise R. Luskin, MD</last_name>
    <phone>617-632-1906</phone>
    <email>Marlise_Luskin@DFCI.HARVARD.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marlise R Luskin, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Jeremy Stewart</last_name>
      <phone>617-582-8063</phone>
      <email>jstewart13@partners.org</email>
    </contact_backup>
    <investigator>
      <last_name>Marlise Luskin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Connolly</last_name>
      <email>CCONNOLLY1@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Hanno Hock, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meredith Nutter, RN</last_name>
      <email>mnutter1@bidmc.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Malgorzata McMasters, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 12, 2018</study_first_submitted>
  <study_first_submitted_qc>July 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2018</study_first_posted>
  <last_update_submitted>October 16, 2019</last_update_submitted>
  <last_update_submitted_qc>October 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Marlise R. Luskin</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>B-cell Acute Lymphoblastic Leukemia</keyword>
  <keyword>Chronic Myeloid Leukemia (CML) in lymphoid blast crisis</keyword>
  <keyword>Philadelphia chromosome positive Acute Lymphoblastic Leukemia (Ph+ ALL).</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Blast Crisis</mesh_term>
    <mesh_term>Philadelphia Chromosome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

